Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Oncopeptides gives with one hand and takes away with the other
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
First-quarter floats see haves pulling away from the have-nots
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.
